Dr. Martina Daly BSc PhD

Senior Lecturer in Molecular Medicine

Address:
Department of Cardiovascular Science
University of Sheffield
Medical School
Beech Hill Road
Sheffield
South Yorkshire
S10 2RX
Tel: +44 (0)114 271 3213
Fax: +44 (0)114 271 1863
Email: m.daly@sheffield.ac.uk

Secretary: Mrs Yvonne Steel
+44(0)114 271 2587
Secretary Email: y.steel@sheffield.ac.uk

Biography:

I joined the University of Sheffield in 1991 when I took up a postdoctoral research post with the Section of Molecular Genetics working with Professor Ian Peake on the investigation of genotype-phenotype relationships in von Willebrand disease. Before this, I completed a PhD in the Children´s Research Centre, Dublin where I developed an interest in haemostasis, in particular antithrombin deficiency, and undertook postdoctoral research posts first in the Children´s Research Centre, Dublin and then in the Department of Haematology, Cambridge UK, where I worked with Professor Robin Carrell´s group on the investigation of the molecular basis of antithrombin deficiency. I was appointed Lecturer in 1992 and Senior Lecturer in 2001.

Research Interests:

My research is aimed at improving understanding of the pathogenesis of inherited haemostatic disorders. Current work is focussed on the contribution of platelet receptor gene variation to the contribution of the bleeding tendency in patients with type 1 von Willebrand factor, and on the identification and characterisation of molecular defects underlying platelet bleeding disorders and inherited thrombocytopenia.

Teaching Interests:

I have a longstanding interest in postgraduate research programmes, and in devising ways to improve the postgraduate research experience. I am currently the Postgraduate Research Lead for the Department of Cardiovascular Science and the University of Sheffield Medical School, and Chair of the Medical School Graduate Research Committee which develops, administers and monitors the assessment of graduate research student progress.

Current Projects:

• Mapping and functional investigation of genetic mutations in patients with mild platelet bleeding disorders. British Heart Foundation funded programme, in collaboration with Prof Steve Watson and Dr Paul Gissen in Birmingham and Drs Andrew Mumford and Stuart Mundell in Bristol.
• The pathogenesis of inherited thrombocytopenia, in collaboration with Dr Mike Makris, Sheffield.

Key Publications:

1. Marsden L, Cox A, Makris M, Daly ME. Lack of Association between Polymorphisms in the Interleukin-1 Gene Cluster and Familial Thrombophilia. Thrombosis Research, in press.
2. Cooper PC, Coath F, Daly ME, Makris M. The phenotypic and genetic assessment of antithrombin deficiency. Int J Lab Hematol, 2011, 33:227-37.
3. Daly ME. Determinants of platelet count in humans. Haematologica, 2011, 96:10-3.
4. Mumford AD, Dawood BB, Daly ME, Murden SL, Williams MD, Protty MB, Spalton JC, Wheatley M, Mundell SJ, Watson SP. A novel thromboxane A2 receptor D304N variant that abrogates ligand binding in a patient with a bleeding diathesis. Blood, 2010, 115:363-9.
5. Watson S, Daly M, Dawood B, Gissen P, Makris M, Mundell S, Wilde J, Mumford A. Phenotypic approaches to gene mapping in platelet function disorders – identification of new variant of P2Y12, TxA2 and GPVI receptors. Hamostaseologie, 2010, 30: 29-38.
6. Daly ME, Dawood BB, Lester WA, Peake IR, Rodeghiero F, Goodeve AC, Makris M, Wilde JT, Mumford AD, Watson SP, Mundell SJ. Identification and characterization of a novel P2Y12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study. Blood, 2009, 113: 4110-3.
7. Smith SM, Judge HM, Peters G, Armstrong M, Fontana P, Gaussem P, Daly ME, Storey RF. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. Platelets, 2006, 17: 250-8.
8. Beauchamp NJ, Dykes AC, Parikh N, Campbell Tait R, Daly ME. The prevalence of, and molecular defects underlying, inherited protein S deficiency in the general population. Br J Haematol, 2004, 125: 647-654.
9. Mollaki V, Steeds RP, Samani NJ, Channer KS, Daly ME. The FcgammaRIIa His131Arg polymorphism and its association with myocardial infarction. J Thromb Haemost, 2004, 2: 1014-5.
10. Daly ME, Makris A, Reed M, Lewis CE. Hemostatic regulators of tumor angiogenesis: a source of antiangiogenic agents for cancer treatment? J Natl Cancer Inst, 2003, 95: 1660-73.
11. Michaux G, Hewlett LJ, Messenger SL, Goodeve AC, Peake IR, Daly ME, Cutler DF. Analysis of intracellular storage and regulated secretion of 3 von Willebrand disease-causing variants of von Willebrand factor. Blood, 2003, 102: 2452-8.
12. Daly ME, Beauchamp NJ. Inherited protein S deficiency: from genotype to phenotype. Haematologica, 2003, 88: 363-7
13. Di Bitondo R, Cameron CL, Daly ME, Croft SA, Steeds RP, Channer KS, Samani NJ, Lillicrap D, Winship PR. The -1185 A/G and -1051 G/A dimorphisms in the von Willebrand factor gene promoter and risk of myocardial infarction. Br J Haematol, 2001, 115: 701-6.
14. Croft SA, Samani NJ, Teare MD, Hampton KK, Steeds RP, Channer KS, Daly ME. Novel platelet membrane glycoprotein VI dimorphism is a risk factor for myocardial infarction. Circulation, 2001, 104: 1459-63.
15. Allen S, Goodeve AC, Peake IR, Daly ME. Endoplasmic reticulum retention and prolonged association of a von Willebrand’s disease-causing von Willebrand factor variant with ERp57 and calnexin. Biochem Biophys Res Commun, 2001, 280: 448-53.

Search PubMed: